Body weight: A risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting

Doniel Drazin, Armen Choulakian, Miriam A Nuno, Penelope Kornbluth, Michael J. Alexander

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Patients with cervical carotid and intracranial stenting are routinely premedicated with antithrombotic agents, clopidogrel and aspirin (ASA), and intraprocedurally with heparin. The levels of antithrombotic therapy necessary for these neurovascular therapies have yet to be well defined. Method: A retrospective review of 52 patients who underwent neurovascular stenting procedures was carried out. Measurements obtained intraoperatively included: activating clotting time, antiplatelet inhibition (from Accumetrics) recorded as ASA reaction units (ARU), P2Y12 reaction units (PRU), baseline (BASE), and percentage inhibition. Percentage P2Y12 platelet inhibition <20% and ARU >550 were defined as suboptimal clopidogrel and ASA responses, respectively. Results: 52 patients (mean age 62.6 years) underwent stent implantation for wide necked aneurysms (28, 54%), symptomatic intracranial stenosis (13, 25%) and cervical carotid stenosis (11, 21%). Mean ARU assays were 463.0±84.7. The response was suboptimal in seven patients. For clopidogrel, the mean BASE, PRU and percentage inhibition were 374.0±54.9, 279.5±78.5 and 30.7%±22.6%, respectively. 19 patients (36.5%; p<0.01) showed suboptimal responses for percentage inhibition. Multivariate analysis showed that body weight (82.0±11 vs 73.6±14 kg; p =0.04) and body mass index were significant predictors (OR 1.18, 95% CI 1.01 to 1.18; p =0.003) in the suboptimal group. One case of intraprocedural thrombosis (2%) was observed in the suboptimal group and no cases were seen in the therapeutic group. Conclusion: Data obtained in this study suggest a suboptimal clopidogrel response in patients with greater body weight and body mass index. Adjusted dosing according to weight may help achieve adequate therapeutic platelet inhibition and reactivity while decreasing thromboembolic complications.

Original languageEnglish (US)
Pages (from-to)177-181
Number of pages5
JournalJournal of NeuroInterventional Surgery
Volume3
Issue number2
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

clopidogrel
Body Weight
Aspirin
Body Mass Index
Therapeutics
Blood Platelets
Fibrinolytic Agents
Carotid Stenosis
Stents
Aneurysm
Heparin
Pathologic Constriction
Thrombosis
Multivariate Analysis

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Body weight : A risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. / Drazin, Doniel; Choulakian, Armen; Nuno, Miriam A; Kornbluth, Penelope; Alexander, Michael J.

In: Journal of NeuroInterventional Surgery, Vol. 3, No. 2, 01.06.2011, p. 177-181.

Research output: Contribution to journalArticle

Drazin, Doniel ; Choulakian, Armen ; Nuno, Miriam A ; Kornbluth, Penelope ; Alexander, Michael J. / Body weight : A risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. In: Journal of NeuroInterventional Surgery. 2011 ; Vol. 3, No. 2. pp. 177-181.
@article{a7f4c3e3f6af479d8dfa4b3a6e41c69f,
title = "Body weight: A risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting",
abstract = "Background: Patients with cervical carotid and intracranial stenting are routinely premedicated with antithrombotic agents, clopidogrel and aspirin (ASA), and intraprocedurally with heparin. The levels of antithrombotic therapy necessary for these neurovascular therapies have yet to be well defined. Method: A retrospective review of 52 patients who underwent neurovascular stenting procedures was carried out. Measurements obtained intraoperatively included: activating clotting time, antiplatelet inhibition (from Accumetrics) recorded as ASA reaction units (ARU), P2Y12 reaction units (PRU), baseline (BASE), and percentage inhibition. Percentage P2Y12 platelet inhibition <20{\%} and ARU >550 were defined as suboptimal clopidogrel and ASA responses, respectively. Results: 52 patients (mean age 62.6 years) underwent stent implantation for wide necked aneurysms (28, 54{\%}), symptomatic intracranial stenosis (13, 25{\%}) and cervical carotid stenosis (11, 21{\%}). Mean ARU assays were 463.0±84.7. The response was suboptimal in seven patients. For clopidogrel, the mean BASE, PRU and percentage inhibition were 374.0±54.9, 279.5±78.5 and 30.7{\%}±22.6{\%}, respectively. 19 patients (36.5{\%}; p<0.01) showed suboptimal responses for percentage inhibition. Multivariate analysis showed that body weight (82.0±11 vs 73.6±14 kg; p =0.04) and body mass index were significant predictors (OR 1.18, 95{\%} CI 1.01 to 1.18; p =0.003) in the suboptimal group. One case of intraprocedural thrombosis (2{\%}) was observed in the suboptimal group and no cases were seen in the therapeutic group. Conclusion: Data obtained in this study suggest a suboptimal clopidogrel response in patients with greater body weight and body mass index. Adjusted dosing according to weight may help achieve adequate therapeutic platelet inhibition and reactivity while decreasing thromboembolic complications.",
author = "Doniel Drazin and Armen Choulakian and Nuno, {Miriam A} and Penelope Kornbluth and Alexander, {Michael J.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1136/jnis.2010.004085",
language = "English (US)",
volume = "3",
pages = "177--181",
journal = "Journal of NeuroInterventional Surgery",
issn = "1759-8478",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Body weight

T2 - A risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting

AU - Drazin, Doniel

AU - Choulakian, Armen

AU - Nuno, Miriam A

AU - Kornbluth, Penelope

AU - Alexander, Michael J.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background: Patients with cervical carotid and intracranial stenting are routinely premedicated with antithrombotic agents, clopidogrel and aspirin (ASA), and intraprocedurally with heparin. The levels of antithrombotic therapy necessary for these neurovascular therapies have yet to be well defined. Method: A retrospective review of 52 patients who underwent neurovascular stenting procedures was carried out. Measurements obtained intraoperatively included: activating clotting time, antiplatelet inhibition (from Accumetrics) recorded as ASA reaction units (ARU), P2Y12 reaction units (PRU), baseline (BASE), and percentage inhibition. Percentage P2Y12 platelet inhibition <20% and ARU >550 were defined as suboptimal clopidogrel and ASA responses, respectively. Results: 52 patients (mean age 62.6 years) underwent stent implantation for wide necked aneurysms (28, 54%), symptomatic intracranial stenosis (13, 25%) and cervical carotid stenosis (11, 21%). Mean ARU assays were 463.0±84.7. The response was suboptimal in seven patients. For clopidogrel, the mean BASE, PRU and percentage inhibition were 374.0±54.9, 279.5±78.5 and 30.7%±22.6%, respectively. 19 patients (36.5%; p<0.01) showed suboptimal responses for percentage inhibition. Multivariate analysis showed that body weight (82.0±11 vs 73.6±14 kg; p =0.04) and body mass index were significant predictors (OR 1.18, 95% CI 1.01 to 1.18; p =0.003) in the suboptimal group. One case of intraprocedural thrombosis (2%) was observed in the suboptimal group and no cases were seen in the therapeutic group. Conclusion: Data obtained in this study suggest a suboptimal clopidogrel response in patients with greater body weight and body mass index. Adjusted dosing according to weight may help achieve adequate therapeutic platelet inhibition and reactivity while decreasing thromboembolic complications.

AB - Background: Patients with cervical carotid and intracranial stenting are routinely premedicated with antithrombotic agents, clopidogrel and aspirin (ASA), and intraprocedurally with heparin. The levels of antithrombotic therapy necessary for these neurovascular therapies have yet to be well defined. Method: A retrospective review of 52 patients who underwent neurovascular stenting procedures was carried out. Measurements obtained intraoperatively included: activating clotting time, antiplatelet inhibition (from Accumetrics) recorded as ASA reaction units (ARU), P2Y12 reaction units (PRU), baseline (BASE), and percentage inhibition. Percentage P2Y12 platelet inhibition <20% and ARU >550 were defined as suboptimal clopidogrel and ASA responses, respectively. Results: 52 patients (mean age 62.6 years) underwent stent implantation for wide necked aneurysms (28, 54%), symptomatic intracranial stenosis (13, 25%) and cervical carotid stenosis (11, 21%). Mean ARU assays were 463.0±84.7. The response was suboptimal in seven patients. For clopidogrel, the mean BASE, PRU and percentage inhibition were 374.0±54.9, 279.5±78.5 and 30.7%±22.6%, respectively. 19 patients (36.5%; p<0.01) showed suboptimal responses for percentage inhibition. Multivariate analysis showed that body weight (82.0±11 vs 73.6±14 kg; p =0.04) and body mass index were significant predictors (OR 1.18, 95% CI 1.01 to 1.18; p =0.003) in the suboptimal group. One case of intraprocedural thrombosis (2%) was observed in the suboptimal group and no cases were seen in the therapeutic group. Conclusion: Data obtained in this study suggest a suboptimal clopidogrel response in patients with greater body weight and body mass index. Adjusted dosing according to weight may help achieve adequate therapeutic platelet inhibition and reactivity while decreasing thromboembolic complications.

UR - http://www.scopus.com/inward/record.url?scp=79958220798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958220798&partnerID=8YFLogxK

U2 - 10.1136/jnis.2010.004085

DO - 10.1136/jnis.2010.004085

M3 - Article

C2 - 21990814

AN - SCOPUS:79958220798

VL - 3

SP - 177

EP - 181

JO - Journal of NeuroInterventional Surgery

JF - Journal of NeuroInterventional Surgery

SN - 1759-8478

IS - 2

ER -